Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 5-6, 2014, Pages 362-370

  Lawton, Kay A ^a   Brown, Meredith V ^a   Alexander, Danny ^a   Li, Zhen ^a   Wulff, Jacob E ^a   Lawson, Robert ^b   Jaffa, Matt ^b   Milburn, Mike V ^a   Ryals, John A ^a   Bowser, Robert ^c   Cudkowicz, Merit E ^b   Berry, James D ^b  

^a METABOLON INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Biomarker; Diagnostics; Metabolomics

Indexed keywords

BIOLOGICAL MARKER; CREATININE; URATE;

ADULT; ALS FUNCTIONAL RATING SCALE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RATING SCALE; SENSITIVITY AND SPECIFICITY; AGED; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; MASS FRAGMENTOGRAPHY; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; SUPPORT VECTOR MACHINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER CURVE; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINES;

EID: 84906343045     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.908311     Document Type: Article

References (51)

1. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population based study. JNeurol Sci. 2006; 250: 45-9
2. Cellura E, Spataro R, Taiello A C, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012; 114: 550-4
3. Weiss R H, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2012; 8: 22-33
4. Johnson C H, Gonzalez F J. Challenges and opportunities of metabolomics. JCell Physiol. 2012; 227: 2975-81
5. Zhang A, Sun H, Wang P, Han Y, Wang X. Recent and potential developments of biofluid analyses in metabolomics. JProteomics. 2012; 75: 1079-88
6. Eckhart AD, Beebe K, Milburn M. Metabolomics as a key integrator for ' omic' adVancement of personalized medicine and future therapies. Clin Transl Sci. 2012; 5: 285-8
7. Milburn M V, Lawton K A, McDunn J E, Ryals J A, Guo L. Understanding Cancer Metabolism Through Global Metabolomics. In: Suhre K, editor. Genetics Meets Metabolomics: From Experiment to Systems Biology: Springer; 2012. pp. 177-90
8. Lawton K A, Cudkowicz M E, Brown M V, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012; 13: 110-8
9. Brooks BR, Miller RG, Swash M, Munsat T L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 293-9
10. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012; 13: 1-10
11. Members M SIB, Sansone S A, Fan T, Goodacre R, Griffin JL, Hardy NW, et al. The metabolomics standards initiative. Nature Biotechnology. 2007; 25: 846-8
12. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). JNeurol Sci. 1999; 169: 13-21
13. Evans AM, DeHaven C D, Barrett T, Mitchell M, Milgram E. Integrated, non-Targeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009; 81: 6656-67
14. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009; 37: 521-35
15. Ward J H J r. Hierarchical Grouping to Optimize an Objective Function. Journal of the American Statistical Association. 1963; 48: 236-44
16. Breiman L. Random Forests. In: S chapire RE, editor. Machine Learning. 45: Kluwer Academic Publishers; 2001. pp. 5-32
17. Cortes C, Vapnik V. Support-vector networks. Machine Learning. 20 (1995). p. 273-97
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B. 1995; 57: 289-300
19. Ganesalingam J, An J, Bowser R, Andersen P M, Shaw C E. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 146-9
20. von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P, Neumann B, et al. Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic. PLoS One. 2012; 7: E44401
21. Verstraete E, Kuiperij HB, van Blitterswijk MM, Veldink JH, Schelhaas HJ, Van Den Berg LH, et al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012; 13: 446-51
22. Tortelli R, Ruggieri M, Cortese R, D'Errico E, Capozzo R, Leo A, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur J Neurol. 2012; 19: 1561-7
23. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011; 6: E25545
24. Wilson M E, Boumaza I, Lacomis D, Bowser R. Cystatin C: A candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2010; 5: E15133
25. Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011; 12: 140-3
26. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010 ;42: 104-11
27. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. ACSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009; 72: 14-9
28. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. Identification of potential CSF biomarkers in ALS. Neurology. 2006; 66: 1218-22
29. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. JNeurochem. 2005; 95: 1461-71
30. Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, et al. Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1-G93A mouse model. Hum Mol Genet. 2013
31. Figueroa-Romero C, Hur J, Bender D E, Delaney C E, Cataldo MD, Smith AL, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One. 2012; 7: E52672
32. Blasco H, Corcia P, Pradat PF, Bocca C, Gordon PH, Veyrat-Durebex C, et al. Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. JProteome Res. 2013; 12: 3746-54
33. Kruger T, Lautenschlager J, Grosskreutz J, Rhode H. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. Proteomics Clin Appl. 2013; 7: 123-35
34. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 113-7
35. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001; 74: 328-34
36. Dupuis L, Oudart H, Rene F, Gonzalez De Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004; 101: 11159-64
37. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld A D, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. JNeurol. 2011; 258: 613-7
38. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008 ;70: 1004-9
39. Dupuis L, Pradat P F, Ludolph AC, Loeffler J P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011; 10: 75-82
40. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, Oudart H, et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One. 2009; 4: E5390
41. Hervias I, Beal M F, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006; 33: 598-608
42. Li Q, Vande Velde C, Israelson A, Xie J, Bailey AO, Dong MQ, et al. ALS-linked mutant superoxide dismutase-1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A. 2010; 107: 21146-51
43. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62
44. Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2002; 2: 215-31
45. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000 ;80: 1107-213
46. Cutler R G, Pedersen W A, Camandola S, Rothstein J D, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002; 52: 448-57
47. Jana A, Hogan EL, Pahan K. Ceramide and neurodegeneration: Susceptibility of neurons and oligodendrocytes to cell damage and death. JNeurol Sci. 2009; 278: 5-15
48. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional Study. Intern Med. 2012; 51: 1501-8
49. Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress? J Neurol Sci. 2009; 285: 95-9
50. Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. JNeurol. 2012 ;259: 1923-8
51. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 37-44